WARNING: TORSADES DE POINTES AND SUDDEN DEATH Cases of Torsades de Pointes, cardiac arrest, and death have been reported with the use of a higher than recommended dosage of loperamide hydrochloride capsules (see WARNINGS and OVERDOSAGE). Loperamide hydrochloride capsules are contraindicated in pediatric patients less than 2 years of age (see CONTRAINDICATIONS). Avoid loperamide hydrochloride capsules dosages higher than recommended in adults and pediatric patients 2 years of age and older due to the risk of serious cardiac adverse reactions (see DOSAGE AND ADMINISTRATION).
Use: Labeled indications
- INDICATIONS AND USAGE Loperamide hydrochloride capsules are indicated for the control and symptomatic relief of acute nonspecific diarrhea in patients 2 years of age and older and of chronic diarrhea in adults…
Full indications and usage US FDA label
INDICATIONS AND USAGE Loperamide hydrochloride capsules are indicated for the control and symptomatic relief of acute nonspecific diarrhea in patients 2 years of age and older and of chronic diarrhea in adults associated with inflammatory bowel disease. Loperamide hydrochloride capsules are also indicated for reducing the volume of discharge from ileostomies.
Contraindications
CONTRAINDICATIONS Loperamide hydrochloride capsules are contraindicated in: pediatric patients less than 2 years of age due to the risks of respiratory depression and serious cardiac adverse reactions (see WARNINGS). patients with a known hypersensitivity to loperamide hydrochloride or to any of the excipients. patients with abdominal pain in the absence of diarrhea. patients with acute dysentery, which is characterized by blood in stools and high fever. patients with acute ulcerative colitis. patients with bacterial enterocolitis caused by invasive organisms including Salmonella, Shigella, and Campylobacter. patients with pseudomembranous colitis (e.g., Clostridium difficle) associated with the use of broad-spectrum antibiotics.
US FDA labelDosing: Adult
Dosage and administration (US label) US FDA label
DOSAGE AND ADMINISTRATION Loperamide hydrochloride capsules USP are contraindicated in pediatric patients less than 2 years of age due to the risks of respiratory depression and serious cardiac adverse reactions (see CONTRAINDICATIONS). Avoid loperamide hydrochloride capsules dosages higher than recommended in adult or pediatric patients 2 years of age and older due to the risk of serious cardiac adverse reactions (see WARNINGS, OVERDOSAGE).
(1 capsule = 2 mg) Patients should receive appropriate fluid and electrolyte replacement as needed. Acute Diarrhea Adults and Pediatric Patients 13 Years and Older: The recommended initial dose is 4 mg (two capsules) followed by 2 mg (one capsule) after each unformed stool. The maximum daily dose is 16 mg (eight capsules).
Clinical improvement is usually observed within 48 hours. Pediatric Patients 2 to 12 Years of Age: In pediatric patients 2 to 5 years of age (20 kg or less), the non-prescription liquid formulation of loperamide (1 mg/5 mL) should be used; for ages 6 to 12, either loperamide hydrochloride capsules or liquid formulation of loperamide may be used.
For pediatric patients 2 to 12 years of age, the following schedule for capsules or liquid will usually fulfill initial dosage requirements: Recommended First Day Dosage Schedule Two to five years (13 kg to 20 kg): 1 mg three times daily (3 mg total daily dosage) Six to eight years (20 kg to 30 kg): 2 mg twice daily (4 mg total daily dosage) Eight to twelve years (greater than 30 kg): 2 mg three times daily (6 mg total daily dosage) Recommended Subsequent Daily Dosage Following the first treatment day, it is recommended that subsequent loperamide hydrochloride capsules doses (1 mg/10 kg body weight) be administered only after a loose stool. Total daily dosage should not exceed recommended dosages for the first day.
Chronic Diarrhea Adults The recommended initial dose is 4 mg (two capsule) followed by 2 mg (one capsule) after each unformed stool until diarrhea is controlled, after which the dosage of loperamide hydrochloride capsules should be reduced to meet individual requirements. When the optimal daily dosage has been established, this amount may then be administered as a single dose or in divided doses.
The average daily maintenance dosage in clinical trials was 4 mg to 8 mg (two to four capsules per day). The maximum daily dosage is 16 mg (eight capsules per day). If clinical improvement is not observed after treatment with 16 mg per day for at least 10 days, symptoms are unlikely to be controlled by further administration.
Loperamide hydrochloride capsules administration may be continued if diarrhea cannot be adequately controlled with diet or specific treatment. Elderly No formal pharmacokinetic studies were conducted in elderly subjects. However, there were no major differences reported in the drug disposition in elderly patients with diarrhea relative to young patients.
No dose adjustment is required for the elderly. In general, elderly patients may be more susceptible to drug-associated effects of the QT interval. Avoid loperamide hydrochloride capsules in elderly patients taking drugs that can result in prolongation of the QT interval (for example, Class IA or III antiarrhythmics) or in patients with risk factors for Torsades de Pointes (see WARNINGS).
Renal Impairment No pharmacokinetic data are available in patients with renal impairment. Since the metabolites and the unchanged drug are mainly excreted in the feces, no dosage adjustment is required for patients with renal impairment (see PRECAUTIONS). Hepatic Impairment The pharmacokinetics of loperamide have not been studied in patients with hepatic impairment.
Use loperamide hydrochloride capsules with caution in such patients because the systemic exposure may be increased due to reduced metabolism (see PRECAUTIONS).
Dosing: Altered kidney function
Renal Impairment No pharmacokinetic data are available in patients with renal impairment. Since the metabolites and the unchanged drug are mainly excreted in the feces, no dosage adjustment is required for patients with renal impairment (see PRECAUTIONS).
Kidney-specific guidance from renalcarematters.com: in preparation.
Dosing: Pediatric
Pediatric use (US label) US FDA label
Pediatric Use Loperamide hydrochloride capsules are contraindicated in pediatric patients less than 2 years of age due to the risks of respiratory depression and serious cardiac adverse reactions (see CONTRAINDICATIONS). Postmarketing cases of cardiac arrest, syncope, and respiratory depression have been reported in pediatric patients less than 2 years of age (see WARNINGS).
Pediatric patients may be more sensitive to CNS effects, such as altered mental status, somnolence, and respiratory depression, than adults. There have been rare reports of paralytic ileus associated with abdominal distention. Most of these reports occurred in the setting of acute dysentery, overdose, and with pediatric patients less than two years of age.
Loperamide hydrochloride capsules should be used with special caution in pediatric patients because of their greater variability of response (see WARNINGS). Dehydration, particularly in pediatric patients less than 6 years of age, may further influence the variability of response to loperamide hydrochloride capsules. The safety and effectiveness of loperamide hydrochloride capsules in pediatric patients with chronic diarrhea have not been established.
Although loperamide hydrochloride capsules have been studied in a limited number of pediatric patients with chronic diarrhea; the therapeutic dose for the treatment of chronic diarrhea in a pediatric population has not been established. In case of accidental overdosage of loperamide hydrochloride capsules by pediatric patients, see OVERDOSAGE for suggested treatment.
Dosage forms
Philippines
- Capsule: 2 mg, 10 mg
- Tablet: 2 mg
Registered products in the Philippines
60 products registered with the Food and Drug Administration (FDA) Philippines list Loperamide as the generic name. Registration status changes; confirm a product's current status on the FDA portal before relying on it.
All registered products60
| Package insert | |||||||
|---|---|---|---|---|---|---|---|
AbydiumLoperamide Hydrochloride | 2 mg CapsuleAlu/PVC Blister Pack x 10’s (Box of 100’s) | Rx | XL Laboratories Pvt. Ltd.India | Ambica International Corporation | DRP-14645 | Apr 21, 2031 | |
AmblomideLoperamide | 2 mg CapsuleAlu/PVC Blister Pack x 10's (Box of 30's and 100's) | Rx | Kanion Pharmaceutical Co., Ltd.China | AMB HK Enterprises, Inc. | DRP-10304 | Sep 8, 2031 | |
ByerrheaLoperamide Hydrochloride | 2 mg CapsuleAlu/Clear PVC Blister Pack x 10's (Box of 100's) | OTC | Brawn Laboratories LimitedIndia | Ambicare Pharmaceuticals Inc.Importer: Ambica International Corporation | DRP-5130-01 | Feb 13, 2029 | |
DatabLoperamide Hydrochloride | 2 mg CapsulePVC Blister Pack x 10's (Box of and 30's); PVC Blister Pack x 10's (Box of 100's) | OTC | Azarias Pharmaceutical Laboratories Inc.Philippines | — | DRP-4358 | Apr 3, 2028 | |
DiacureLoperamide Hydrochloride | 2 mg CapsuleAlu-PVC/PVDC Blister Pack x 10's (Box of 30's and 100's) | Rx | Fredun Pharmaceuticals LimitedIndia | PhilRx Pharma Inc.Importer: AMB HK Enterprises Inc. | DRP-9045 | Aug 7, 2030 | |
DiakhrizLoperamide | 2 mg Capsule | OTC | Merit Organics Ltd.India | Khriz Pharma Trading Inc | DRP-17733 | Feb 24, 2031 | |
DialomideLoperamide Hydrochloride | 2 mg CapsuleBlister Pack x 10's (Box of 100's) | Rx | Diamond Laboratories Inc.Philippines | — | DRP-7212 | Feb 12, 2032 | |
DiamideLoperamide HCl | 2 mg TabletAlu/Alu Blister Pack x 10's (Box of 10's, 30's and 100's) | OTC | Phil. United Pharma CorporationPhilippines | ATC HEALTHCARE INTERNATIONAL CORPORATION | DRP-11216 | Feb 15, 2027 | |
DiarelLoperamide hydrochloride | 2 mg CapsuleAlu/PVC Blister Pack x 10's (Box of 100's) | Rx | Zee LaboratoriesIndia | Importer: EON PHARMATEK INC | DR-XY47138 | Dec 28, 2030 | |
DiasolvLoperamide Hydrochloride | 2 mg CapsuleAlu/PVC Blister Pack x 10's (Box of 100's) | OTC | Lloyd Laboratories, Inc.Philippines | Trader: Westfield Pharmaceuticals, Inc. | DRP-9365 | Mar 2, 2029 | |
DiastopLoperamide Hydrochloride | 2 mg CapsuleAlu/Clear PVC Blister Pack x 10’s (Box of 100’s) | OTC | Flamingo Pharmaceuticals Ltd.India | Hexagon Pharmaceuticals | DRP-1886 | Sep 13, 2029 | |
DiatabsLoperamide Hydrochloride | 2 mg CapsuleAluminum Foil Strip x 4's (Box of 100's); Aluminum Foil Strip x 4's (Box of 500's); Aluminum Foil Strip x 4's (Envelope of 1's) | OTC | UNILAB, Inc.Philippines | — | DR-XY24964 | Mar 15, 2029 | |
DocmideLoperamide Hydrochloride | 2 mg TabletAlu/Alu Blister Pack x 10's (Box of 10's, 30's and 100's) | OTC | Phil. United Pharma CorporationCavite | Trader: Docteur's Choice Corporation | DRP-10206 | Aug 6, 2031 | |
GolmideLoperamide Hydrochloride | 2 mg CapsuleAlu/PVC Blister Pack x 10's (Box of 10's, 30's, and 100's); Alu/PVC Blister Pack x 10's Box of 30's; Alu/PVC Blister Pack x 10's Box of 100's | OTC | Phil. United Pharma CorporationCavite | Trader: Golden Dale Pharma Corp. | DRP-10339 | Sep 14, 2031 | |
GolmideLoperamide Hydrochloride | 2 mg TabletAlu/Alu Blister Pack x 10's (Box of 10's, 30's, and 100's) | OTC | Phil. United Pharma Corp.Philippines | Golden Dale Pharma Corp. | DRP-13298 | Jan 19, 2028 | |
GoperamideLoperamide | 2mg CapsuleAlu-PVC Blister Pack of 10's (Box of 100's) | OTC | Ratnatris Pharmaceuticals Pvt. Ltd.India | Go Healthcare Pharmaceutical DistributionImporter: Medinova Pharmaceutical Inc | DRP-12190-01 | Jun 28, 2027 | |
GopramideLoperamide Hydrochloride | 2 mg CapsuleAlu/Clear PVC Blister Pack x 10's (Box of 100's) | OTC | Brawn Laboratories LimitedIndia | Applied Pharmaceutical Distribution Inc.Importer: Ambica International Corporation | DRP-5130-02 | Feb 13, 2029 | |
HarvimideLoperamide (as hydrochloride) | 2 mg CapsuleBlister Pack x 10's (Box of 100's) | OTC | Scheele Laboratories Phils., IncPhilippines | — | DR-XY22591-B | Mar 21, 2031 | |
ImodiumLoperamide hydrochloride | 2 mg CapsuleBlister Pack x 2's (Box of 4's); Blister Pack x 10's (Box of 10's); Blister Pack x 10's (Box of 200's) | OTC | Interphil Laboratories, Inc.Philippines | Johnson & Johnson (Philippines), Inc | DR-XY14916 | Jul 7, 2028 | |
ImotabLoperamide hydrochloride | 2 mg CapsulePVC Blister Pack x 10's (Box of 30's and 100's) | OTC | Azarias Pharmaceutical Laboratories Inc.Philippines | — | DRP-4378 | Mar 18, 2028 | |
KoramideLoperamide hydrochloride | 2 mg CapsulePVC Blister Pack x 10's (Box of 100's) | OTC | Azarias Pharmaceutical Laboratories Inc.Philippines | Konzept Convenience and Drug Store Corp. | DRP-4378-06 | Mar 18, 2028 | |
LomotilLoperamide Hydrochloride | 2 mg TabletBlister Pack x 10's (Box of 100's) | Rx | Interphil Laboratories, IncPhilippines | JNTL Consumer Health (Philippines) Inc. | DR-XY27914 | Mar 10, 2031 | |
LoniperLoperamide Hydrochloride | 2 mg CapsuleAlu/Clear PVC Blister Pack x 10's (Box of 100's) | Rx | Lloyd Laboratories, Inc.Philippines | TGP Pharma Inc.Trader: Foramen Products Corporation | DRP-297 | Oct 8, 2030 | |
LopediumLoperamide Hydrochloride | 2 mg CapsuleAlu-PVC Blister Pack x 10 (Box of 100's) | OTC | Ratnatris Pharmaceuticals Private LimitedIndia | GA2 Pharmaceutical Inc.Importer: Medinova Pharmaceutical Inc. | DRP-12190-02 | Jun 28, 2027 | |
LopegenLoperamide Hydrochloride | 2 mg CapsulePVC Blister Pack x 10's (Box of 30's and 100's) | OTC | Azarias Pharmaceutical Laboratories Inc.Philippines | Eba Generisch Trading Inc. | DRP-4378-01 | Mar 18, 2028 | |
LopelifeLoperamide Hydrochloride | 2 mg CapsuleAlu-PVC Blister Pack x 10 (Box of 100's) | OTC | Ratnatris Pharmaceuticals Private LimitedIndia | Life And Health Source Pharmaceutical Distribution Co.Importer: Medinova Pharmaceutical Inc. | DRP-12190-04 | Jun 28, 2027 | |
LopemidLoperamide hydrochloride | 2 mg CapsulePVC Blister Pack x 10's (Box of 30's and 100's) | OTC | Azarias Pharmaceutical Laboratories Inc.Philippines | St. Raphael Archangel Pharmaceutical Product Distribution | DRP-4378-03 | Mar 18, 2028 | |
LoperaCapLoperamide Hydrochloride | 2mg CapsulePVC-Alu Blister Pack x 10’s (Box of 10’s); PVC-Alu Blister Pack x 10’s (Box of 30’s) | OTC | Phil. United Pharma CorporationPhilippines | ATC HEALTHCARE INTERNATIONAL CORP. | DR-XY46224 | Jan 24, 2028 | |
LoperamedLoperamide Hydrochloride | 2 mg CapsuleAlu-PVC Blister Pack x 10 (Box of 100's) | OTC | Ratnamani Healthcare Pvt. Ltd.India | Medinova Pharmaceutical Inc. | DRP-12190 | Jun 28, 2027 | |
LoperazanLoperamide Hydrochloride | 2 mg CapsulePVC Blister Pack x 10's (Box of and 30's and 100's) | OTC | Azarias Pharmaceutical Laboratories Inc.Philippines | Triple 888 Medical And Pharma Inc. | DRP-4358-01 | Apr 3, 2028 | |
LopranLoperamide Hydrochloride | 2 mg CapsuleAlu/Clear PVC Blister Pack x 10's (Box of 100's) | OTC | Brawn Laboratories LimitedIndia | Ambica International Corporation | DRP-5130 | Feb 13, 2029 | |
LorbanLoperamide Hydrochloride | 2 mg CapsuleAlu/Clear PVC Blister Pack x 10's Box of 100's | OTC | Lloyd Laboratories, Inc.Philippines | Trader: Medhaus Pharma, Inc. | DR-XY25228 | May 25, 2029 | |
MonclomideLoperamide | 2 mg CapsuleBlister Pack x 10's (Box of 100's) | OTC | Scheele Laboratories Phils., Inc.Philippines | 999 Seth Pharmaceutical Inc. | DRP-164-02 | Feb 25, 2027 | |
MotilesLoperamide Hydrochloride | 2 mg CapsuleAlu/PVC Blister Pack x 10's (Box of 100's) | OTC | Saga Lifesciences LimitedIndia | Hexagon Pharmaceuticals | DR-XY46603 | Jun 4, 2029 | |
MotirexLoperamide Hydrochloride | 2 mg CapsuleClear PVC/Alu Blister Pack x 20's (Box of 100's) | OTC | New Myrex Laboratories, Inc.Philippines | — | DR-XY38945 | Jan 13, 2030 | |
NodiaLoperamide Hydrochloride | 2 mg CapsuleAlu/PVC Blister Pack x 10's (Box of 100's) | OTC | Saga Lifesciences LimitedIndia | Hexagon Pharmaceuticals | DR-XY46607 | Jun 4, 2029 | |
NoneLoperamide Hydrochloride | 2 mg CapsuleAluminum Foil Strip x 4's (Box of 100's) | OTC | Interphil Laboratories, Inc.Philippines | Icon Healthcare, Inc. | DRP-1911-02 | Jun 3, 2031 | |
NoneLoperamide Hydrochloride | 2 mg CapsuleAluminum Foil Strip x 4's (Box of 100's) | OTC | Interphil Laboratories, Inc.Philippines | South Star Drug | DRP-1911-03 | Aug 10, 2031 | |
NoneLoperamide hydrochloride | 2 mg CapsulePVC Blister Pack x 10's (Box of 100's) | OTC | Azarias Pharmaceutical Laboratories Inc.Philippines | BEWISE TRADING CORP. Doing business under the name & style of PHARMAPLUS GENERIC & BRANDED DRUG DISTRIBUTOR & MEDICAL SUPPLIES | DRP-4378-07 | Mar 18, 2028 | |
NoneLoperamide Hydrochloride | 2 mg CapsuleBlister pack x 20's (Box of 100's) | Rx | Drugmaker's Laboratories Inc.Philippines | — | DRP-5554 | Aug 3, 2030 | |
NoneLoperamide Hydrochloride | 2 mg CapsuleBlister Pack x 10's (Box of 100's); Blister Foil x 10's (Envelope Pack); Blister Pack x 10's (Box of 10's) | Rx | Am-Europharma CorporationPhilippines | Personal Collection Direct Selling, Inc. | DRP-562 | Oct 10, 2031 | |
NoneLoperamide Hydrochloride | 2 mg CapsuleBlister Pack x 10's (Box of 100's) | OTC | Am-Europharma CorporationPhilippines | Onesource Pharma Solutions, Inc. | DRP-562-05 | Jul 30, 2031 | |
NoneLoperamide | 2 mg CapsuleAlu/Clear PVC Blister Pack x 10's (Box of 100's) | OTC | Lloyd Laboratories, Inc.Philippines | Actimed, Inc.Trader: Innogen Pharmaceuticals, Inc. | DRP-7091 | May 22, 2029 | |
NoneLoperamide Hydrochloride | 2 mg CapsuleAlu/Clear PVC Blister Pack x 10's (Box of 100's) | OTC | Lloyd Laboratories, Inc.Philippines | Dr. Zen’s Research, Inc.Trader: Innogen Pharmaceuticals, Inc. | DRP-7091-02 | May 22, 2029 | |
NoneLoperamide Hydrochloride | 2 mg CapsuleAlu/PVC Blister Pack x 10's (Box of 100's) | OTC | Lloyd Laboratories, Inc.Philippines | Watsons Personal Care Stores (Philippines), Inc.Trader: Westfield Pharmaceuticals, Inc. | DRP-9365-01 | Mar 2, 2029 | |
NoneLoperamide Hydrochloride | 2mg CapsuleAlu/Clear PVC Blister Pack x 10's (Box of 100's) | Rx | Eurasia Research Pharma CorporationPhilippines | — | DR-XY45225 | Apr 1, 2031 | |
RamideLoperamide hydrochloride | 2 mg CapsulePVC Blister Pack x 10's (Box of 30's and 100's) | OTC | Azarias Pharmaceutical Laboratories Inc.Philippines | St. Raphael Archangel Pharmaceutical Product Distribution | DRP-4378-04 | Mar 18, 2028 | |
RetamideLoperamide Hydrochloride | 2 mg CapsuleAlu-PVC Blister Pack x 10 (Box of 100's) | OTC | Ratnatris Pharmaceuticals Private LimitedIndia | Reta DrugImporter: Medinova Pharmaceutical Inc. | DRP-12190-03 | Jun 28, 2027 | |
RexamideLoperamide | 10 mg CapsuleAlu/Clear PVC Blister Pack x 10's (Box of 100's) | OTC | Next Wave (India)India | Aarex Pharma Distributor | DRP-12314 | Jul 13, 2027 | |
SpasmobanLoperamide Hydrochloride | 2 mg CapsuleAluminum Foil Strip x 4's (Box of 100's); , Aluminum Foil Strip x 2's (Physician's Sample) | OTC | Interphil Laboratories, Inc.Philippines | — | DRP-1911 | Mar 15, 2031 | |
TGP-LoperLoperamide Hydrochloride | 2 mg CapsuleClear PVC/Alu Blister Pack x 20's (Box of 100's) | Rx | New Myrex Laboratories, Inc.Philippines | TGP Pharma Inc. | DR-XY38833 | Dec 8, 2030 | |
UnbrandedLoperamide Hydrochloride | 2 mg CapsuleAluminum Foil Strip x 4's (Box of 100's) | OTC | Interphil Laboratories, Inc.Philippines | Rose Pharmacy, Incorporated | DRP-1911-01 | Jun 17, 2031 | |
UnbrandedLoperamide Hydrochloride | 2 mg CapsuleAlu/Clear PVC Blister Pack x 10's (Box of 100's) | OTC | Lloyd Laboratories, Inc.Philippines | Gamot Philippines, Inc.Trader: Foramen Products Corporation | DRP-297-04 | Aug 6, 2031 | |
UnbrandedLoperamide Hydrochloride | 2 mg CapsuleBlister Pack x 10's (Box of 100's) | OTC | AM-Europharma CorporationPhilippines | RITEMED PHILS., INC. | DRP-562-01 | Oct 30, 2031 | |
UnbrandedLoperamide Hydrochloride | 2 mg TabletAlu/Red PVC Blister Pack X 25's (Box of 100's) | Rx | Vonwelt Inc.Philippines | — | DRP-7806 | Nov 14, 2031 | |
UnbrandedLoperamide | Tablet 2 mgAlu/Alu Blister Pack x 10's (Box of 10's, 30's and 100's) | Rx | Phil. United Pharma CorporationPhilippines | — | DRP-9686 | May 5, 2031 | |
United Home LormideLoperamide Hydrochloride | 2 mg CapsuleAluminum Foil Strip Pack x 4's (Box of 100's) | OTC | Amherst Laboratories, Inc.Philippines | Trader: UNILAB, Inc. | DR-X6084 | May 24, 2027 | |
VexilLoperamide Hydrochloride | 2 mg CapsuleAlu/Clear PVC Blister Pack x 10’s (Box of 100’s) | OTC | Genom Biotech Pvt. Ltd.India | Nelpa Lifesciences, Inc. | DRP-8679 | Aug 24, 2031 | |
(no brand name)Loperamide Hydrochloride | 2 mg CapsuleAlu/Clear PVC Blister Pack x 20's (Box of 100's) | OTC | Vonwelt Inc.Philippines | — | DRP-13569 | Jul 22, 2029 | |
(no brand name)Loperamide Hydrochloride | 2 mg CapsuleAlu/PVC Blister Pack x 10's (Box of 100's) | OTC | Scheele Laboratories Phils., Inc.Philippines | — | DRP-17043 | Sep 12, 2030 |
Source: FDA Philippines product registration database. "Valid until" is the registration validity date listed by the FDA; a past date may mean a renewal is pending. Package insert links point to files published by the FDA.
Warnings/Precautions
The boxed warning is shown at the top of this page.
Warnings and precautions (US label) US FDA label
WARNINGS Cardiac Adverse Reactions, Including Torsades de Pointes and Sudden Death Cases of prolongation of the QT/QTc interval, Torsades de Pointes, other ventricular arrhythmias, cardiac arrest, some resulting in death, have been reported in adults with use of higher than recommended doses per day of loperamide hydrochloride capsules. Cases include patients who were abusing or misusing loperamide hydrochloride (see OVERDOSAGE and DRUG ABUSE AND DEPENDENCE).
Cases of syncope and ventricular tachycardia have been reported in adult patients receiving the recommended dosage of loperamide hydrochloride capsules. Some of these patients were taking other drugs or had other risk factors that may have increased their risk of cardiac adverse reactions. Additionally, postmarketing cases of cardiac arrest, syncope, and respiratory depression have been reported in pediatric patients less than 2 years of age.
Loperamide hydrochloride capsules are contraindicated in pediatric patients less than 2 years of age due to the risks of respiratory depression and serious cardiac adverse reactions. Avoid loperamide hydrochloride capsules dosages higher than recommended in adults and pediatric patients 2 years of age and older due to the risk of serious cardiac adverse reactions (see DOSAGE AND ADMINISTRATION and OVERDOSAGE).
Avoid loperamide hydrochloride capsules in: combination with others drugs or herbal products that are known to prolong the QT interval, including Class 1A (e.g., quinidine, procainamide) or Class III (e.g., amiodarone, sotalol) antiarrhythmics, antipsychotics (e.g., chlorpromazine, haloperidol, thioridazine, ziprasidone), antibiotics (e.g., moxifloxacin), or any other drug known to prolong the QT interval (e.g., pentamidine, levomethadyl acetate, methadone). patients with risk factors for QT prolongation, including patients with congenital long QT syndrome, with a history of cardiac arrhythmias or other cardiac conditions, elderly patients and those with electrolyte abnormalities. Dehydration Fluid and electrolyte depletion often occur in patients who have diarrhea.
In such cases, administration of appropriate fluid and electrolytes is very important. The use of loperamide hydrochloride capsules does not preclude the need for appropriate fluid and electrolyte therapy. Gastrointestinal Disorders In general, loperamide hydrochloride capsules should not be used when inhibition of peristalsis is to be avoided due to the possible risk of significant sequelae including ileus, megacolon and toxic megacolon.
Loperamide hydrochloride capsules must be discontinued promptly when constipation, abdominal distention or ileus develop. Treatment of diarrhea with loperamide hydrochloride capsules is only symptomatic. Whenever an underlying etiology can be determined, specific treatment should be given when appropriate (or when indicated).
Patients with AIDS treated with loperamide hydrochloride capsules for diarrhea should have therapy stopped at the earliest signs of abdominal distention. There have been isolated reports of toxic megacolon in AIDS patients with infectious colitis from both viral and bacterial pathogens treated with loperamide hydrochloride.
Variability in Pediatric Response Loperamide hydrochloride capsules should be used with special caution in pediatric patients because of the greater variability of response in this age group. Dehydration, particularly in pediatric patients less than 6 years of age, may further influence the variability of response to loperamide hydrochloride capsules.
Loperamide hydrochloride capsules are contraindicated in pediatric patients less than 2 years of age due to the risks of respiratory depression and serious cardiac adverse reactions.
Drug interactions
Drug interactions (US label) US FDA label
Drug Interactions Effects of Other Drugs on Loperamide Concomitant use of loperamide hydrochloride capsules with inhibitors of CYP3A4 (e.g., itraconazole) or CYP2C8 (e.g., gemfibrozil) or inhibitors of P-glycoprotein (e.g., quinidine, ritonavir) can increase exposure to loperamide. The increased systemic exposure to loperamide may increase a risk for cardiac adverse reactions especially in patients who are taking multiple CYP enzyme inhibitors, or in patients with underlying cardiac conditions (see WARNINGS).
Monitor patients for cardiac adverse reactions. CYP3A4 Inhibitors Itraconazole Concomitant administration of multiple doses of 100 mg itraconazole twice daily, an inhibitor of both CYP3A4 and P-glycoprotein, with a single 4 mg dose of loperamide hydrochloride increased the peak plasma concentration and the systemic exposure to loperamide by 2.9-fold and 3.8-fold, respectively.
CYP2C8 Inhibitors Gemfibrozil When a single 4 mg dose of loperamide hydrochloride was coadministered with 600 mg gemfibrozil, a strong inhibitor of CYP2C8, on day 3 of a 5-day treatment with gemfibrozil twice daily, the mean peak plasma concentration and the systemic exposure to loperamide was increased by 1.6-fold and 2.2-fold, respectively. CYP3A4 and CYP2C8 Inhibitors When multiple doses of both 100 mg itraconazole and 600 mg gemfibrozil twice daily were administered with a single 4 mg dose of loperamide hydrochloride, the mean peak plasma concentration and the systemic exposure to loperamide was increased by 4.2-fold and 12.6-fold, respectively.
P-glycoprotein Inhibitors Concomitant administration of a 16 mg single dose of loperamide hydrochloride with a 600 mg single dose of quinidine or ritonavir, both of which are P-glycoprotein inhibitors, resulted in a 2- to 3-fold increase in loperamide plasma concentrations. Due to the potential for enhanced CNS adverse reactions when loperamide is coadministered with quinidine and with ritonavir, caution should be exercised when loperamide hydrochloride capsules are administered at the recommended dosages (2 mg, up to 16 mg maximum daily dose) with P-glycoprotein inhibitors.
Effects of Loperamide on Other Drugs Saquinavir When a single 16 mg dose of loperamide hydrochloride is coadministered with a 600 mg single dose of saquinavir, loperamide decreased saquinavir exposure by 54%, which may be of clinical relevance due to reduction of therapeutic efficacy of saquinavir. The effect of saquinavir on loperamide is of less clinical significance.
Therefore, when loperamide hydrochloride capsules are given with saquinavir, the therapeutic efficacy of saquinavir should be closely monitored. Carcinogenesis, Mutagenesis, Impairment of Fertility In an 18-month rat study with oral loperamide hydrochloride doses up to 40 mg/kg/day (21 times the maximum human dose of 16 mg/day, based on a body surface area comparison), there was no evidence of carcinogenesis.
Loperamide was not genotoxic in the Ames test, the SOS chromotest in E. coli, the dominant lethal test in female mice, or the mouse embryo cell transformation assay. Fertility and reproductive performance was evaluated in rats using oral doses of 2.5 mg/kg/day, 10 mg/kg/day, and 40 mg/kg/day (females only) in a second study.
Oral administration of 20 mg/kg/day (approximately 11 times the human dose based on a body surface area comparison) and higher, produced a strong impairment of female fertility. Treatment of female rats with up to 10 mg/kg/day (approximately 5 times the human dose based on a body surface area comparison) had no effect on fertility.
Treatment of male rats with oral doses of 40 mg/kg/day (approximately 21 times the human dose based on a body surface area comparison) produced impairment of male fertility, whereas administration of up to 10 mg/kg/day (approximately 5 times the human dose based on a body surface area comparison) had no effect.
Metabolism and transporters (CYP, P-gp, OATP; US label) US FDA label
Loperamide is a P-glycoprotein substrate.
Metabolism In vitro loperamide is metabolized mainly by cytochrome P450 (CYP450) isozymes, CYP2C8 and CYP3A4, to form- N-demethyl loperamide.
In an in vitro study, quercetin (CYP2C8 inhibitor) and ketoconazole (CYP3A4 inhibitor) significantly inhibited the N-demethylation process by 40% and 90%, respectively.
In addition, CYP2B6 and CYP2D6 appear to play a minor role in loperamide N- demethylation.
Concomitant use of loperamide hydrochloride with inhibitors of CYP3A4 (e.g., itraconazole) or CYP2C8 (e.g., gemfibrozil) or inhibitors of P-glycoprotein (e.g., quinidine, ritonavir) can increase exposure to loperamide (see PRECAUTIONS : Drug Interactions ).
Drug Interactions Effects of Other Drugs on Loperamide Concomitant use of loperamide hydrochloride capsules with inhibitors of CYP3A4 (e.g., itraconazole) or CYP2C8 (e.g., gemfibrozil) or inhibitors of P-glycoprotein (e.g., quinidine, ritonavir) can increase exposure to loperamide.
CYP3A4 Inhibitors Itraconazole Concomitant administration of multiple doses of 100 mg itraconazole twice daily, an inhibitor of both CYP3A4 and P-glycoprotein, with a single 4 mg dose of loperamide hydrochloride increased the peak plasma concentration and the systemic exposure to loperamide by 2.9-fold and 3.8-fold, respectively.
CYP2C8 Inhibitors Gemfibrozil When a single 4 mg dose of loperamide hydrochloride was coadministered with 600 mg gemfibrozil, a strong inhibitor of CYP2C8, on day 3 of a 5-day treatment with gemfibrozil twice daily, the mean peak plasma concentration and the systemic exposure to loperamide was increased by 1.6-fold and 2.2-fold, respectively.
Adverse reactions
Adverse reactions (US label) US FDA label
ADVERSE REACTIONS Clinical Trial Experience The adverse effects reported during clinical investigations of loperamide hydrochloride capsules are difficult to distinguish from symptoms associated with the diarrheal syndrome. Adverse experiences recorded during clinical studies with loperamide hydrochloride capsules were generally of a minor and self-limiting nature.
They were more commonly observed during the treatment of chronic diarrhea. The adverse events reported are summarized irrespective of the causality assessment of the investigators. 1) Adverse events from 4 placebo-controlled studies in patients with acute diarrhea The adverse events with an incidence of 1.0% or greater, which were reported at least as often in patients on loperamide hydrochloride as on placebo, are presented in the table below.
Acute Diarrhea Loperamide Hydrochloride Placebo No. of treated patients 231 236 Gastrointestinal AE% Constipation 2.6% 0.8% The adverse events with an incidence of 1.0% or greater, which were more frequently reported in patients on placebo than on loperamide hydrochloride, were: dry mouth, flatulence, abdominal cramp and colic. 2) Adverse events from 20 placebo-controlled studies in patients with chronic diarrhea The adverse events with an incidence of 1.0% or greater, which were reported at least as often in patients on loperamide hydrochloride as on placebo, are presented in the table below. Chronic Diarrhea Loperamide Hydrochloride Placebo No. of treated patients 285 277 Gastrointestinal AE% Constipation 5.3% 0.0% Central and peripheral nervous system AE% Dizziness 1.4% 0.7% The adverse events with an incidence of 1.0% or greater, which were more frequently reported in patients on placebo than on loperamide hydrochloride were: nausea, vomiting, headache, meteorism, abdominal pain, abdominal cramp and colic. 3) Adverse events from 76 controlled and uncontrolled studies in patients with acute or chronic diarrhea The adverse events with an incidence of 1.0% or greater in patients from all studies are given in the table below.
Acute Diarrhea Chronic Diarrhea All Studies a No. of treated patients 1913 1371 3740 Gastrointestinal AE% Nausea 0.7% 3.2% 1.8% Constipation 1.6% 1.9% 1.7% Abdominal cramps 0.5% 3.0% 1.4% All patients in all studies, including those in which it was not specified if the adverse events occurred in patients with acute or chronic diarrhea. Postmarketing Experience The following adverse events have been reported: Cardiac Disorders QT/QTc-interval prolongation, Torsades de Pointes, other ventricular arrhythmias, cardiac arrest, syncope, and death (see WARNINGS and OVERDOSAGE).
Skin and Subcutaneous Tissue Disorders Rash, pruritus, urticaria, angioedema, and extremely rare cases of bullous eruption including erythema multiforme, Stevens-Johnson syndrome and Toxic Epidermal Necrolysis have been reported with use of loperamide hydrochloride capsules. Immune System Disorders Isolated occurrences of allergic reactions and in some cases severe hypersensitivity reactions including anaphylactic shock and anaphylactoid reactions have been reported with the use of loperamide hydrochloride capsules.
Gastrointestinal Disorders Dry mouth, abdominal pain, distention or discomfort, nausea, vomiting, flatulence, dyspepsia, constipation, paralytic ileus, megacolon; including toxic megacolon (see CONTRAINDICATIONS, WARNINGS). Renal and Urinary Disorders Urinary retention Nervous System Disorders Drowsiness, dizziness General Disorders and Administrative Site Conditions Tiredness A number of the adverse events reported during the clinical investigations and postmarketing experience with loperamide are frequent symptoms of the underlying diarrheal syndrome (abdominal pain/discomfort, nausea, vomiting, dry mouth, tiredness, drowsiness, dizziness, constipation, and flatulence).
These symptoms are often difficult to distinguish from undesirable drug effects.
Adverse reaction frequency tables (US label) US FDA label
| Acute Diarrhea | ||
| Loperamide Hydrochloride | Placebo | |
| No. of treated patients | 231 | 236 |
| Gastrointestinal AE% Constipation | 2.6% | 0.8% |
| Chronic Diarrhea | ||
| Loperamide Hydrochloride | Placebo | |
| No. of treated patients | 285 | 277 |
| Gastrointestinal AE% Constipation | 5.3% | 0.0% |
| Central and peripheral nervous system AE% Dizziness | 1.4% | 0.7% |
| Acute Diarrhea | Chronic Diarrhea | All Studies a | |
| No. of treated patients | 1913 | 1371 | 3740 |
| Gastrointestinal AE% Nausea | 0.7% | 3.2% | 1.8% |
| Constipation | 1.6% | 1.9% | 1.7% |
| Abdominal cramps | 0.5% | 3.0% | 1.4% |
Pregnancy considerations
Pregnancy (US label) US FDA label
Pregnancy Teratogenic Effects. Teratology studies have been performed in rats using oral loperamide hydrochloride doses of 2.5 mg/kg/day, 10 mg/kg/day, and 40 mg/kg/day, and in rabbits using oral doses of 5 mg/kg/day, 20 mg/kg/day, and 40 mg/kg/day. These studies have revealed no evidence of impaired fertility or harm to the fetus at doses up to 10 mg/kg/day in rats (5 times the human dose based on body surface area comparison) and 40 mg/kg/day in rabbits (43 times the human dose based on body surface area comparison).
Treatment of rats with oral doses of 40 mg/kg/day (21 times the human dose based on a body surface area comparison) produced marked impairment of fertility. The studies produced no evidence of teratogenic activity. There are no adequate and well controlled studies in pregnant women. Loperamide hydrochloride capsules should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.
Non-Teratogenic Effects In a peri- and post-natal development study in rats, oral administration of 40 mg/kg/day produced impairment of growth and survival of offspring.
Breastfeeding considerations
Lactation (US label) US FDA label
Nursing Mothers Small amounts of loperamide may appear in human breast milk. Therefore, loperamide hydrochloride capsules are not recommended during breast-feeding.
Pharmacokinetics
Elimination The apparent elimination half-life of loperamide is 10.8 hours with a range of 9.1 to 14.4 hours.
Excretion Excretion of the unchanged loperamide and its metabolites mainly occurs through the feces.
Pharmacokinetics (US label) US FDA label
CLINICAL PHARMACOLOGY Mechanism of Action In vitro and animal studies show that loperamide hydrochloride capsules act by slowing intestinal motility and by affecting water and electrolyte movement through the bowel. Loperamide binds to the opiate receptor in the gut wall. Consequently, it inhibits the release of acetylcholine and prostaglandins, thereby reducing propulsive peristalsis, and increasing intestinal transit time.
Loperamide increases the tone of the anal sphincter, thereby reducing incontinence and urgency. Pharmacodynamics Loperamide prolongs the transit time of the intestinal contents. It reduces daily fecal volume, increases the viscosity and bulk density, and diminishes the loss of fluid and electrolytes. Tolerance to the antidiarrheal effect has not been observed.
Pharmacokinetics Absorption Plasma concentrations of unchanged drug remain below 2 ng/mL after the intake of a 2 mg capsule of loperamide hydrochloride. Plasma loperamide concentrations are highest approximately 5 hours after administration of the capsule and 2.5 hours after the liquid. The peak plasma concentrations of loperamide were similar for both formulations.
Distribution Based on literature information, the plasma protein binding of loperamide is about 95%. Loperamide is a P-glycoprotein substrate. Elimination The apparent elimination half-life of loperamide is 10.8 hours with a range of 9.1 to 14.4 hours. Elimination of loperamide mainly occurs by oxidative N-demethylation. Metabolism In vitro loperamide is metabolized mainly by cytochrome P450 (CYP450) isozymes, CYP2C8 and CYP3A4, to form- N-demethyl loperamide.
In an in vitro study, quercetin (CYP2C8 inhibitor) and ketoconazole (CYP3A4 inhibitor) significantly inhibited the N-demethylation process by 40% and 90%, respectively. In addition, CYP2B6 and CYP2D6 appear to play a minor role in loperamide N- demethylation. Concomitant use of loperamide hydrochloride with inhibitors of CYP3A4 (e.g., itraconazole) or CYP2C8 (e.g., gemfibrozil) or inhibitors of P-glycoprotein (e.g., quinidine, ritonavir) can increase exposure to loperamide (see PRECAUTIONS: Drug Interactions).
Excretion Excretion of the unchanged loperamide and its metabolites mainly occurs through the feces.
Formulary and pricing (Philippines)
Government price references
| Preparation | Price (PHP) | Unit | Type |
|---|---|---|---|
| Loperamide Hydrochloride 2 mg Capsule | ₱0.45–₱3.00Reference ₱0.92 | per capsule | DPRI procurement range |
Range = lowest-highest procurement price (highest usable only in GIDA areas); reference_price = 2021 DPRI ceiling (median)
These are government procurement and reimbursement references, not retail prices. Sources:
- DOH Drug Price Reference Index (DPRI) 2021, 9th edition (as of September 17, 2021); https://caro.doh.gov.ph/wp-content/uploads/2021/09/2021DPRI-as-of-9-17-2021.pdf, as of September 17, 2021
Formulary and coverage
| Philippine National Formulary | Listed as Loperamide (as hydrochloride) |
| PNF listing | Oral: 2 mg capsule (N.B.: Not for infants and children less than 12 years old) |
| PhilHealth GAMOT | No |
Sources:
- PNF Essential Medicines List, 8th ed. (as of November 2, 2022), DOH; https://www.philhealth.gov.ph/partners/providers/pdf/PNF-EML_11022022.pdf, as of November 2, 2022
Check availability
Prices and stock vary by branch; renalcarematters.com does not sell medicines or receive payment from pharmacies.
References
- U.S. Food and Drug Administration. Loperamide Hydrochloride · Advagen Pharma Ltd., [US FDA-approved label, version 3, January 5, 2026]. Via DailyMed/openFDA. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=03c907d5-87f8-47a6-9544-5a24f5272739
- Food and Drug Administration Philippines. Verification portal (product registrations). https://verification.fda.gov.ph
- PNF Essential Medicines List, 8th ed. (as of November 2, 2022), DOH; https://www.philhealth.gov.ph/partners/providers/pdf/PNF-EML_11022022.pdf
- DOH Drug Price Reference Index (DPRI) 2021, 9th edition (as of September 17, 2021); https://caro.doh.gov.ph/wp-content/uploads/2021/09/2021DPRI-as-of-9-17-2021.pdf
This page shows official label and registry text only; no renalcarematters.com clinical summary has been approved for it yet.
Last updated: .